GlobalData on MSN9h
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC studyBristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback